Patients injecting compounded semaglutide for weight loss are overdosing at alarming rates, flooding poison control centers with calls tied to preventable dosing mistakes. The FDA has received adverse-event reports of overdoses from compounded injectable semaglutide products, with some cases serious enough to require hospitalization. A published case series documented 10-fold dosing errors traced to confusion over measurement units, mismatched syringes, and a lack of patient counseling, all problems that do not arise with the prefilled pens used for brand-name drugs like Ozempic and Wegovy.
How unit confusion turns a weight-loss shot into a poison-control call
The core problem is deceptively simple. Brand-name GLP-1 medications ship in prefilled injection pens with fixed dose increments. Compounded versions arrive in multi-dose vials, and patients must draw up the correct volume themselves using a separate syringe. That extra step introduces multiple failure points. The FDA has identified confusion among milliliters, milligrams, and units as a recurring cause of overdose reports, along with syringe size mismatches and varying concentrations across products from different compounding pharmacies.
When a patient receives a vial labeled in milligrams per milliliter but reads the syringe markings in units, the math can go wrong fast. A case series published in Clinical Toxicology found that poison control centers fielded reports of administration and dosing errors involving compounded semaglutide in vials and syringes, with 10-fold overdoses documented in some instances. The study pointed to a lack of pharmacist counseling as a direct contributor: patients who would normally receive hands-on instruction with a prefilled pen were instead left to interpret vial labels and syringe graduations on their own.
These are not marginal miscalculations. A patient prescribed 0.25 milligrams who accidentally draws up 2.5 milligrams is injecting a dose that exceeds even the highest FDA-approved maintenance level for semaglutide. Symptoms of overdose can include severe nausea, vomiting, and gastrointestinal distress serious enough to send someone to the emergency room. In some cases, patients have required observation for prolonged vomiting, dehydration, and electrolyte abnormalities, all stemming from a single misdrawn dose.
Compounded products can also vary in appearance and packaging, which complicates patient education. Two vials from different pharmacies may contain different concentrations but look nearly identical on a kitchen counter. If a patient is told to “use 10 units on the syringe” without understanding that those units correspond to a specific concentration, a switch in suppliers can silently transform a stable regimen into an overdose risk.
FDA safety alerts and the compounding enforcement shift
The agency has not treated these reports as isolated incidents. The FDA consolidated its safety concerns about unapproved compounded semaglutide and tirzepatide products on a dedicated hub page, documenting dosing and titration errors that include doses exceeding approved labels, as well as reports of hospitalizations and other serious outcomes tied to these compounded formulations. That hub underscores the distinction between approved brand-name drugs and unapproved compounded copies, stressing that compounded products have not undergone the same premarket review for safety, effectiveness, or quality.
The regulatory backdrop makes the dosing crisis harder to contain. Compounded semaglutide proliferated during national shortages of brand-name GLP-1 drugs, when the FDA exercised enforcement discretion and allowed compounding pharmacies to produce copies of drugs still under patent protection. As supplies recover, that discretion is narrowing, and the agency is signaling a shift back toward tighter control over copies of commercially available products.
One thread in that tightening web is the FDA’s import oversight. The agency has used an import alert to flag certain semaglutide products offered by unapproved or unregistered sources, allowing field staff to detain shipments without physical examination. While this tool primarily targets foreign or gray-market products, it reflects broader concerns about the quality and labeling of semaglutide outside the approved drug supply chain.
At the same time, the FDA’s postmarket safety communications for GLP-1 medications have expanded to include compounded formulations. The agency’s information for patients and providers on semaglutide-containing medications highlights reports of dosing errors, off-label use, and adverse events linked to products that are not FDA-approved. That communication urges prescribers to consider whether a compounded version is truly necessary and to counsel patients carefully on how to measure and inject each dose.
Yet even as enforcement tools strengthen, they do not retroactively fix the vials and syringes already in patients’ refrigerators. Many individuals began compounded therapy during shortage conditions and may still be refilling from the same pharmacies. Others may have leftover vials they continue to use while transitioning to brand-name pens. The risk of misdosing does not disappear simply because supply constraints have eased on paper.
Unanswered questions about compounded semaglutide overdose rates
Several critical data gaps prevent a full accounting of the problem. America’s Poison Centers, which operates the National Poison Data System, has not published aggregate call volumes and outcomes specific to compounded GLP-1 products. Without that data, it is impossible to know whether the Clinical Toxicology case series represents a fraction of total incidents or the bulk of them. The FDA’s adverse-event database similarly lacks publicly released line-item details on the exact concentrations, syringe sizes, and patient instructions that produced each reported overdose.
There is also no public record showing how many compounding facilities have changed their labeling, standardized their concentrations, or paired vials with appropriately calibrated syringes in response to safety alerts. Some pharmacies may now provide color-coded instructions, pictograms, or in-person teaching, while others may still dispense a vial with minimal guidance beyond a printed label. In the absence of uniform standards, patient safety hinges on the practices of individual compounders and prescribers.
The lack of transparency extends to outcomes. Poison control data can capture the immediate clinical picture-nausea, vomiting, abdominal pain, and the need for emergency care-but longer-term follow-up is sparse. It is not clear how many patients abandon treatment after a frightening overdose, how many develop persistent aversions to injections or medical care, or how many quietly resume therapy with lingering anxiety about every dose they draw.
What safer use would look like
Experts who study medication errors often emphasize that the burden should not fall solely on patients to “be more careful.” Instead, safer systems are designed to make the correct action the easiest one to take. For compounded semaglutide, that could mean standardizing concentrations so that every milliliter contains the same amount of drug regardless of pharmacy, pairing each vial with a syringe whose markings directly match the prescribed dose, and requiring clear, plain-language instructions that translate milligrams into the exact line on the syringe barrel.
Prescribers can also play a pivotal role. Before opting for a compounded product, clinicians can verify that a patient truly lacks access to an approved alternative, explain the differences between pens and vials, and demonstrate how to measure a dose using the specific syringe provided. Pharmacists, in turn, can reinforce that teaching at the point of dispensing, asking patients to perform a teach-back-drawing up a mock dose of saline, for example-to confirm understanding before they leave the pharmacy.
Ultimately, the surge in preventable overdoses reflects a mismatch between a complex dosing system and the everyday realities of patients trying to manage chronic conditions at home. Until labeling, concentration, and counseling practices catch up-or until compounded semaglutide recedes as shortages ease-poison control centers are likely to remain on the front lines, fielding calls from people who thought they were taking a routine weight-loss shot and discovered too late that they had misread the lines on a syringe.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
